Generic Name: durvalumab

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Immunotherapy Medications

Company: AstraZeneca

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Imfinzi is a checkpoint inhiibtor approved for advanced or metastatic bladder (urothelial) cancer and inoperable non-small-cell lung cancer.

General Info

Imfinzi is a monoclonal antibody used in cancer immunotherapy. It is a checkpoint inhibitor that blocks the PD-L1 protein on cancer cells or immune cells in tumors. PD-1 is an immune checkpoint on T cells that plays a role in regulating immune function. Some tumors can hijack PD-1 to turn off immune responses against them. Drugs that block the interaction between PD-1 and PD-L1, its binding partner, can release the brakes and restore T-cell activity.

Clinical trials showed that Imfinzi slows progression of bladder cancer and non-small-cell lung cancer. 

It was first approved in 2017.


Dosing Info:

Imfinzi is administered as an intravenous infusion. The usual dose for adults is 10 mg/kg every two weeks.

Side Effects

Common side effects include fatigue, cough, shortness of breath, upper respiratory tract infections and skin rash. Checkpoint inhibitors can cause an overactive immune response that harms healthy organs and tissues. Serious immune-mediated side effects can affect almost any organ including the lungs (known as pneumonitis), liver, kidneys, intestines, skin and hormone-producing endocrine glands.

For More Info:

Co-Pay Program Info:

Patient Assistance Program Info:

Last Reviewed: September 17, 2018